Advancing hepatic cell carcinoma treatment through mitochondrial DNA targeting

FHS
July 29, 2024
6:25 pm

Hepatic cell carcinoma (HCC), the fifth most prevalent malignancy worldwide and the fourth leading cause of cancer-related mortality, poses significant therapeutic challenges.

Sionna raises $182m to double down in cystic fibrosis drug development – Pharmaceutical Technology

Share this article The round secures funding for the company through 2026. Image credit: Shutterstock/OlekStock. Sionna Therapeutics has continued raising capital, closing a $182m Series

March 7, 2024

Lawmakers renew calls for government to finalize march-in guidance

Sens. Elizabeth Warren (D-MA) and Angus King (I-ME), and Rep. Lloyd Doggett (D-TX) are once again urging the federal government to “immediately strengthen and finalize

August 13, 2024

Historic low sector valuations – Biotech Investments

Edison Investment Research Limited The Biotech Growth Trust: Historic low sector valuations 09-Oct-2023 / 07:15 GMT/BST The issuer is solely responsible for the content of

October 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.